Related references
Note: Only part of the references are listed.Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
Simona Soverini et al.
MOLECULAR CANCER (2018)
T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system
Minori Tamai et al.
SCIENTIFIC REPORTS (2018)
THE INFLUENCE OF FIBRONECTIN ON PROLIFERATION AND APOPTO SIS OF ACUTE LYMPHOBLASTIC LEUKAEMIA CELLS IN VITRO
Joanna Wlodek et al.
POLISH JOURNAL OF PATHOLOGY (2018)
Integrin-Linked Kinase Expression in Myeloid Cells Promotes Inflammatory Signaling during Experimental Colitis
Afsar U. Ahmed et al.
JOURNAL OF IMMUNOLOGY (2017)
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
Andrew A. Wylie et al.
NATURE (2017)
The molecular mechanisms of chemoresistance in cancers
Hua-Chuan Zheng
ONCOTARGET (2017)
Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting
Jennifer Peyling Wang et al.
JOURNAL OF CANCER (2017)
Single-Molecule Localization Microscopy in Eukaryotes
Markus Sauer et al.
CHEMICAL REVIEWS (2017)
Focal adhesion kinase is required for actin polymerization and remodeling of the cytoskeleton during sperm capacitation
Ana L. Roa-Espitia et al.
BIOLOGY OPEN (2016)
A hostel for the hostile: the bone marrow niche in hematologic neoplasms
Daniela S. Krause et al.
HAEMATOLOGICA (2015)
Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia
Pilar de la Puente et al.
LEUKEMIA RESEARCH (2015)
Integrin-linked kinase regulates the niche of quiescent epidermal stem cells
Jessica Morgner et al.
NATURE COMMUNICATIONS (2015)
A hostel for the hostile: the bone marrow niche in hematologic neoplasms
Daniela S. Krause et al.
HAEMATOLOGICA (2015)
Overexpression of fibronectin confers cell adhesion-mediated drug resistance ( CAM- DR) against 5-FU in oral squamous cell carcinoma cells
Yoshihiro Nakagawa et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
Simona Soverini et al.
LEUKEMIA RESEARCH (2014)
ILK: a pseudokinase with a unique function in the integrin-actin linkage
Sushmita Ghatak et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2013)
In Vivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling
Peter G. Miller et al.
CANCER CELL (2013)
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis
Franck E. Nicolini et al.
HAEMATOLOGICA (2013)
Influence of tumour micro-environment heterogeneity on therapeutic response
Melissa R. Junttila et al.
NATURE (2013)
Differential regulation of myeloid leukemias by the bone marrow microenvironment
Daniela S. Krause et al.
NATURE MEDICINE (2013)
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Ashley Hamilton et al.
BLOOD (2012)
Integrin-linked kinase at a glance
Moritz Widmaier et al.
JOURNAL OF CELL SCIENCE (2012)
Focal Adhesion Kinase Stabilizes the Cytoskeleton
Ben Fabry et al.
BIOPHYSICAL JOURNAL (2011)
Differential niche and Wnt requirements during acute myeloid leukemia progression
Steven W. Lane et al.
BLOOD (2011)
Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor
Soo-Hyun Kim et al.
JOURNAL OF ENDOCRINOLOGY (2011)
Fibronectin Protects from Excessive Liver Fibrosis by Modulating the Availability of and Responsiveness of Stellate Cells to Active TGF-β
Nina Kawelke et al.
PLOS ONE (2011)
Integrin-Linked Kinase Regulates Migration and Proliferation of Human Intestinal Cells Under a Fibronectin-Dependent Mechanism
David Gagne et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2010)
ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines
Valentina Nardi et al.
BLOOD (2009)
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Susan Branford et al.
BLOOD (2009)
Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche
Cristina Lo Celso et al.
NATURE (2009)
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
Michael G. Kharas et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
Brian J. Skaggs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice
Yiguo Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells
Daniela S. Krause et al.
NATURE MEDICINE (2006)
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9
Andrei V. Krivtsov et al.
NATURE (2006)
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib
Ian J. Griswold et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients:: a retrospective analysis from the French intergroup of CML (Fi(φ)-LMC GROUP)
F. E. Nicolini et al.
LEUKEMIA (2006)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
alpha IIb integrin, a novel marker for hemopoietic progenitor cells
C Corbel et al.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2005)
Integrin-linked kinase: A cancer therapeutic target unique among its ILK
G Hannigan et al.
NATURE REVIEWS CANCER (2005)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells
KD Cheng et al.
CANCER (2002)
Regulation of fibronectin matrix deposition and cell proliferation by the PINCH-ILK-CH-ILKBP complex
L Guo et al.
FASEB JOURNAL (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Share Paper
